We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies
US drugs maker also says low pricing of NHS purchases risks harming Britain’s push in life sciences
Companies have raised hundreds of millions of dollars despite a troubled biotech market
Deal is latest in a series of bolt-on acquisitions by pharmaceutical companies
US pharma company agrees four-year deal with Oxford-based Exscientia
US pharmaceutical group can avoid shareholder involvement in MyoKardia acquisition
MyoKardia deal is US company’s first major acquisition since Celgene last year
Deal helps advance Bristol-Myers Squibb’s $90bn takeover of rival biotech giant Celgene
Offering is the largest bond issue of 2019 so far
The US pharmaceutical company beat expectations on earnings and revenue in the first quarter
Activist investor Starboard ends proxy fight after ISS and Glass Lewis support takeover
Wellington’s intervention in Bristol-Myers M&A battle could prove a turning point
Drugmaker has faced pushback from shareholders, including institutional investor Wellington
Activist Starboard joins Wellington Management joins fight against industry megamerger
Activist fund the latest to publicly criticise drugmaker’s planned $90bn takeover
Some companies pledge to lower costs if government reforms rebate system
Politicians to grill pharma executives over what is fast becoming a key election issue
Starboard’s demand for board seats raises questions over $90bn pharma deal
Bristol-Myers Squibb and Celgene $90bn merger ranks among most lucrative for banks
Drugmaker withdraws FDA application for combination treatment
BMS claims acquisition will result in 40% boost to annual earnings per share
Bristol-Myers Squibb’s $90bn takeover sets stage for big pharma M&A in 2019
Cash-and-stock offer ranks as one of biggest ever pharma deals
International Edition
